Clinical Trials Logo

Bacterial Infections clinical trials

View clinical trials related to Bacterial Infections.

Filter by:

NCT ID: NCT01018641 Completed - Clinical trials for Bacterial Infections

An Evaluation Of Three Dose Levels Of 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) In Healthy Adults

Start date: January 2010
Phase: Phase 1
Study type: Interventional

This study is a first-in-human (Phase 1) study using three dose levels of an investigational vaccine directed against Staphylococcus aureus (SA3Ag). This study is primarily designed to assess how safe and well tolerated SA3Ag is, but will also describe the immune response over 12 months elicited by SA3Ag. Additionally, this study will assess the effect of SA3Ag vaccine on the number of Staphylococcus aureus bacteria that naturally occur on the skin and within the nose and throat.

NCT ID: NCT01015014 Completed - Clinical trials for Gram-negative Bacterial Infection

Safety, Pharmacokinetics (PK) and Tolerability Study of a Novel Drug for Treatment of Bacterial Infections

Start date: November 5, 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetic profile of an antibacterial compound for treatment of hospital acquired Gram negative infection.

NCT ID: NCT01012089 Completed - Clinical trials for Chronic Kidney Disease

Study of the Pharmacokinetics of Daptomycin in Children With Renal Disease

Start date: November 2009
Phase: N/A
Study type: Interventional

The purpose of this study is to: 1. Study the pharmacokinetics and safety of daptomycin in children on hemodialysis (HD) and peritoneal dialysis (PD). 2. Determine urine, HD and PD clearance of daptomycin.

NCT ID: NCT00998309 Completed - Clinical trials for Bacterial Infections

Zithromax-SR 2g, Special Investigation (Regulatory Post Marketing Commitment Plan)

Start date: October 2009
Phase: N/A
Study type: Observational

To collect the efficacy and safety information of Zithromax-SR related to their appropriate use in daily practice.

NCT ID: NCT00983255 Completed - Clinical trials for Bacterial Infections

Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA)

IV/SAD/MAD
Start date: September 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of single rising and multiple rising IV doses of TR-701 FA and to determine the absolute bioavailability of oral TR-701 FA following single oral and IV dose administrations in healthy adult subjects.

NCT ID: NCT00965848 Completed - Infection Clinical Trials

A Safety and Efficacy Study of Doripenem in Participants With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Urinary Tract Infections

Start date: June 2009
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess the safety and efficacy of doripenem in participants with nosocomial pneumonia (inflammation of the lungs in which the lungs become heavy; pneumonia occurring at least 48 hours after hospital admission), complicated intra-abdominal (in belly) infections and complicated urinary tract infections (bladder infections).

NCT ID: NCT00945152 Recruiting - Clinical trials for Bacterial Infections

Effects of MRSA Bactericidal Gel To Promote Healing and Eliminate MRSA in cSSTI Vancogel(TM)

Vancogel(R)
Start date: July 15, 2011
Phase: Phase 2
Study type: Interventional

Based on personal experience and the literature it is reasonable expectation that Vancomycin is a viable treatment in a direct contact form to eliminate MRSA from open wounds in order to heal the wounds by conventional means. The key question in my research has been to measure the effectiveness of my Vancomycin Gel by culturing the wound, applying the Gel in a controlled manner and then culturing the wound after one week. The end point to achieve in the process, is a clinical response of accelerated healing and negative culture report. Another question to solve is the duration of potency and stability of the Vancomycin gel over time.

NCT ID: NCT00945087 Recruiting - Clinical trials for Bacterial Infections

Experimental Phage Therapy of Bacterial Infections

Start date: December 2005
Phase: N/A
Study type: Interventional

The primary purpose of this experimental therapy is to treat, with the aid of bacteriophages, patients with non-healing postoperative wounds or bone, upper respiratory tract, genital or urinary tract infections in whom extensive antibiotic therapy failed or the use of the targeted drug is contraindicated.

NCT ID: NCT00939562 Completed - Bacterial Infection Clinical Trials

Bioequivalence Between Two Tablet Formulations Of Doxycycline Carragenate

Start date: November 2008
Phase: Phase 4
Study type: Interventional

The purpose of this protocol is to study if two different tablet formulations of doxycycline are bioequivalent to each other.

NCT ID: NCT00924911 Completed - Clinical trials for Infections, Bacterial

Relative Bioavailability Study in Healthy Subjects

PDF112034
Start date: April 27, 2009
Phase: Phase 1
Study type: Interventional

Part 1 of this study will assess the relative bioavailability of GSK1322322 administered as one of three investigational tablets compared to powder in a bottle formulation. Pharmacokinetics of these three tablets will be evaluated and the investigation tablet with the optimal PK profile will be progressed to Part 2. In Part 2 the investigational tablet selected from Part 1 will be coadministered with food alone, an H2 blocker alone, or an H2 blocker given in combination with ascorbic acid to evaluate the effect on GSK1322322 pharmacokinetics. Plasma GSK1322322 PK profile, safety, and tolerability will be assessed from each dose group.